DNER and nut midline carcinoma: As indicated in one study, after taking a novel oral BET inhibitor named OTX015/MK-8628, which is able to target BRD2/3/4/T with impressive preclinical and rapid antitumour activity against NMC, two patients achieved notably longer overall survival (19 and 18 months, respectively) than the median survival of 6.7 months reported in the largest retrospective series of patients with NMC [18].